Freeline Therapeutics Holdings plc
DelistedCIK 1810031fmd_0Y4PD4QAPZ5QMC45M01W1F8S7JManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Sep 30, 2023, 18 periods
Latest annual · FY2022
Millions- Operating income
- (98)
- Net income
- (89)
- Free cash flow
- (85)
Latest quarter · Q3 FY2023
Millions- Total revenues
- 0
- Operating income
- (12)
- Net income
- (12)
- Free cash flow
- (9)
Freeline Therapeutics Holdings plc financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Operating income | -$98.4 million | -$142.4 million | 20-F 2023-04-04 · proof | |
| Net income | -$89 million | -$140.4 million | 20-F 2023-04-04 · proof | |
| Cash from operating activities | -$78.2 million | -$107.6 million | 20-F 2023-04-04 · proof | |
| Free cash flow | -$85.2 million | -$111.8 million | 20-F 2023-04-04 · proof | |
| Total assets | $86.6 million | $141.1 million | -38.6% | 20-F 2023-04-04 · proof |
| Total liabilities | $34.2 million | $20.7 million | +65.5% | 20-F 2023-04-04 · proof |
| Cash and cash equivalents | $47.3 million | $117.7 million | -59.8% | 20-F 2023-04-04 · proof |
- What was Freeline Therapeutics Holdings plc's operating income in fiscal 2022?
- Freeline Therapeutics Holdings plc reported operating income of -$98.4 million for fiscal 2022 (the year ended Dec 31, 2022), against -$142.4 million the year before. Source: the 20-F filed with the SEC on Apr 4, 2023. SEC
- What was Freeline Therapeutics Holdings plc's net income in fiscal 2022?
- Freeline Therapeutics Holdings plc reported net income of -$89 million for fiscal 2022 (the year ended Dec 31, 2022), against -$140.4 million the year before. Source: the 20-F filed with the SEC on Apr 4, 2023. SEC
- What was Freeline Therapeutics Holdings plc's cash from operating activities in fiscal 2022?
- Freeline Therapeutics Holdings plc reported cash from operating activities of -$78.2 million for fiscal 2022 (the year ended Dec 31, 2022), against -$107.6 million the year before. Source: the 20-F filed with the SEC on Apr 4, 2023. SEC
- What was Freeline Therapeutics Holdings plc's free cash flow in fiscal 2022?
- Freeline Therapeutics Holdings plc reported free cash flow of -$85.2 million for fiscal 2022 (the year ended Dec 31, 2022), against -$111.8 million the year before. Source: the 20-F filed with the SEC on Apr 4, 2023. SEC
- What are Freeline Therapeutics Holdings plc's total assets?
- As of Dec 31, 2022, Freeline Therapeutics Holdings plc reported total assets of $86.6 million, against $141.1 million a year earlier (-38.6%). Source: the 20-F filed with the SEC on Apr 4, 2023. SEC
- What are Freeline Therapeutics Holdings plc's total liabilities?
- As of Dec 31, 2022, Freeline Therapeutics Holdings plc reported total liabilities of $34.2 million, against $20.7 million a year earlier (+65.5%). Source: the 20-F filed with the SEC on Apr 4, 2023. SEC
- What are Freeline Therapeutics Holdings plc's cash and cash equivalents?
- As of Dec 31, 2022, Freeline Therapeutics Holdings plc reported cash and cash equivalents of $47.3 million, against $117.7 million a year earlier (-59.8%). Source: the 20-F filed with the SEC on Apr 4, 2023. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1810031&period_type=annual&limit=5"Information only, not investment advice.